Cargando…
Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies
Bispecific antibodies have moved from being an academic curiosity with therapeutic promise to reality, with two molecules being currently commercialized (Hemlibra(®) and Blincyto(®)) and many more in clinical trials. The success of bispecific antibodies is mainly due to the continuously growing numb...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6182456/ https://www.ncbi.nlm.nih.gov/pubmed/30132211 http://dx.doi.org/10.1007/s40259-018-0299-9 |